Despite the achievements that have increased viability after the transplantation of allogeneic hematopoietic stem cells (aHSCT), chronic graft-versus-host disease (cGVHD) remains the main cause of late complications and post-transplant deaths. At the moment, therapy alternatives demonstrate limited effectiveness in steroid-refractory illness; in addition, we have no reliable data on the mechanism of this condition. The lack of drugs of choice for the treatment of GVHD underscores the significance of the design of new therapies. Improved understanding of the mechanism of chronic GVHD has secured new therapy goals, and organized diagnostic recommendations and the development of medical tests have ensured a general language and routes for studies in this field. These factors, combined with the rapid development of pharmacology, have helped speed up the search of medicines and medical studies regarding chronic GVHD. At present, we can hope for success in curing this formidable complication. This review summarizes the latest clinical developments in new treatments for chronic GVHD.
1 April 2015 in Russian Journal of Pediatric Hematology and Oncology
X-Linked lymphoproliferative syndrome (XLP) is a primary immunodeficiency characterized by atypical reaction to Epstein-Barr virus (EBV), resulting in the development of hemophagocytosis, disgammaglobulinemia, and, depending on the syndrome type, malignant lymphoproliferation. Three types of XLP are known. XLP type 1 is a result of mutation in the SH2D1A gene encoding SAP adapter molecule. This XLP type is characterized by predisposition to EBV infection, hemophagocytic lymphohistiocytosis (HLH), disgammaglobulinemia, and malignant lymphoproliferation. XLP type 2 is similar to XLP type 1 by some clinical manifestations, such as predisposition to EBV infection and high risk of HLH, but differs from type 1 by the pathogenesis, development of hemorrhagic colitis, and absence of lymphomas. The clinical manifestations of XLP type 2 develop as a result of defects in XIAP gene, also known as BIRC4 gene, encoding an antiapoptotic protein. XLP type 3, caused by loss-of-function _ mutations in the gene encoding magnesium transporter 1 (MAGT1), has been recently discovered. In addition, several autosomal recessive syndromes with a similar XLP clinical manifestation - EBV-associated lymphoproliferation, with ITK, CD27, and CORO1A genes defects, are known. Clinical case reports of the most incident XLP types 1 and 2 are presented.
29 May 2015 in Russian Journal of Pediatric Hematology and Oncology
В статье представлена схема мониторинга поздних осложнений у детей после проведения им трансплантации гемопоэтических стволовых клеток (ТГСК), а также особенности диспансеризации этих больных, как в специализированных, так и в лечебно-профилактических учреждениях по месту жительства. Приведено краткое описание поздних осложнений, их диагностики и лечения. Данная публикация предназначена для врачей, проводящих различные виды ТГСК, детских онкогематологов, гематологов, иммунологов и педиатров, осуществляющих наблюдение за детьми с онкогематологической и иммунологической патологией на местах, а также для врачей узкой специализации (эндокринологов, невропатологов, окулистов, гинекологов, кардиологов, гастроэнтерологов, нефрологов и др.).
Secondary malignant diseases are dangerous long-term complications of allogeneic hematopoietic stem cell transplantation (HSCT). This article describes the group of secondary lymphoid neoplasms and presents a rare case of secondary Hodgkin disease in a 21-year patient 6 years after HSCT due to acute myeloid leukemia. This complication should be distinguished from the Hodgkin-like posttransplant lymphoproliferative disease, because of the different therapy approaches and outcomes. We describe their main features and differential diagnostic procedures.
Hematopoietic stem cells transplantation (HSCT) technology currently allows curing a lot of malignant and non-malignant diseases in adults and children. However, HSCT is highly toxic treatment. HSCT complications include the possibility of prolonged immunodeficiency, alloand autoimmune reactions and various organs dysfunction. These conditions require careful monitoring by specialists, early diagnosis and appropriate treatment. This article discusses the clinical features, diagnosis and treatment options of such late complications as non-infectious lung disease. These conditions can lead to disability of patients. Relevance and importance of timely diagnosis of these pathological conditions, including the range of clinical tests available on a residence, with a view to effective treatment can improve the quality of life ofchildren with complications after HSCT. Theoretical issues are illustrated by case report.